Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 11, 2025
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -
Read more at globenewswire.comNASDAQ:DRTSW (10/20/2025, 8:00:01 PM)
0.3051
-0.02 (-5.4%)
NASDAQ:DRTS (10/20/2025, 8:00:01 PM)
4
+0.25 (+6.67%)
Find more stocks in the Stock Screener
